Evaluate the Future of SLUSH AORN Booth 2052 - New Orleans 4-Liter Freezer Supply Multiple ORs SLUSH

Re-Usable, Hydrophobic Always Smooth Slush


cited risk assessment/prevention activi- ties, clinical record audits, and provider credentialing and privileging all benefi ted from the AAAHC accreditation process. The AAAHC 2017 ROI Survey gathered responses from approximately 400 ambu- latory organizations to determine how ac- creditation positively impacts operations and outcomes. The results showed three areas that

benefi ted the most: • 88% reported implementing new risk as- sessment/prevention activities, policies or procedures: Adoption of new activi- ties such as checklists and screening for VTE, sleep apnea and depression

• 83% cited performance on clinical re- cords audit: Using a robust audit and tracking system with a more structured audit process, as well as conducting quality improvement (QI) studies

Protective Container Tamper-Evident Security

•79% stated provider credentialing and privileging processes: Following AAAHC standards, conducting more audits, standardizing forms and using a credentialing verifi cation organization Additional aspects of ambulatory care that respondents reported were most positively impacted by the AAAHC ac- creditation process include: • Care Coordination • Management of care for patients with high health care needs

• Delivery of preventative care • Patient and provider engagement • Access to care • Coordination of care across providers in the community

2-Liter Freezer Economical

• Patient Safety/Quality of Care • Reduced adverse events or near misses • Reduced falls • Satisfaction

• Patient, provider and staff • Financial performance • Increased third-party payer contracts and reimbursement rates

• Decreased facility liability costs

92% of Evaluations Purchase (adoption/purchase rate previous 120 days)

No Contracts You Have Full Control



FDA and NRC pave way for fi rst domestic supply of isotope used in diagnostic imaging The U.S. Food and Drug Administration and the Nuclear Regulatory Commission (NRC) took steps to ensure a stable and secure supply of a critical radioactive imag- ing product used to detect potentially life- threatening diseases. The FDA approved the RadioGenix System, a unique system for producing Technetium-99m (Tc-99m), the most widely used radioisotope in medi- cal imaging. The NRC is issuing guidance and will license the RadioGenix System to enable the Tc-99m it produces to be used for its medical purpose.

Tc-99m is a diagnostic agent that is used by healthcare professionals with FDA-ap- proved imaging devices to detect potential diseases like coronary artery disease and cancer, as well as evaluating lung, liver, kidney and brain function. When used with the appropriate diagnostic scanner device, such as a SPECT imaging system, the Tc-99m emits signals that are captured and produces an image of internal organs to detect various medical problems and contribute to diagnosis and treatment decisions.

Tc-99m has been in use as a medical imaging diagnostic agent for decades and is used in more than 80 percent of nuclear medicine imaging procedures in the U.S. Before today, Molybdenum-99, or Mo-99, the parent of Tc-99m, could only be pro- duced from enriched uranium by several facilities outside of the U.S. This required a complicated supply chain that involved shipping enriched uranium from the U.S. This left the U.S. vulnerable to possible shortages and/or supply chain issues. To address these challenges, Congress

enacted the American Medical Isotopes Production Act of 2012, which contained provisions to eliminate the use of highly enriched uranium for medical isotope production and encouraged the develop- ment of U.S. domestic supplies of Mo-99 and associated isotopes. As such, multiple federal agencies – including the FDA, NRC, as well as the Department of Energy’s National Nuclear Security Administration and National Laboratories, among others – have been working together with industry for several years to develop a technology that helps to minimize the industry’s de- pendence on highly enriched uranium and brings the supply chain within the U.S. As a result of this collaboration, the U.S. medi- cal community will now have a domestic source of Tc-99m through the use of the RadioGenix System, which marks the fi rst non-uranium process for the production of Mo-99 to prepare the Tc-99m.

As the regulatory authority responsible for overseeing the production, distribution, possession and use of radioactive materials and products containing radioactive ma- terials, NRC is issuing guidance that will advise medical and commercial nuclear pharmacy users on the license amendments they will need to possess and use the Radio- Genix System. The approval of RadioGenix System was granted to NorthStar Medical Radioisotopes. Healthcare providers should ensure safe

handling to protect patients and health care workers from unintentional radiation exposure in accordance with instructions for use in the product labeling. HPN

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82